KPV
Animal-onlyLysine-Proline-Valine · Lys-Pro-Val · alpha-MSH (11-13) · α-MSH (11-13)
Limited evidence: the strongest curated study is Animal-only — no human-trial data found as of 2026-06-04. State this honestly.
Chemical & identity
- Molecular formula
- C16H30N4O4
- Molecular weight
- 342.43 g/mol · PubChem
- PubChem CID
- 125672 · PubChem
- SMILES
- CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N
- InChIKey
- YSPZCHGIWAQVKQ-AVGNSLFASA-N
- Category
- Anti-inflammatory
Chemical/structural fields are auto-pulled and source-linked.
Mechanism (curated)
No established mechanism of action has been curated yet.
Research
Xiao B et al. · Molecular therapy : the journal of the American Society of Gene Therapy · 2017 · Animal study
This study evaluated hyaluronic acid-functionalized nanoparticles loaded with KPV (lysine-proline-valine), a tripeptide shown to reduce inflammatory responses in colonic cells, for treating ulcerative colitis. In an animal model (mouse), oral administration of HA-KPV-NPs encapsulated in a chitosan/alginate hydrogel demonstrated superior efficacy compared to KPV-NP/hydrogel without hyaluronic acid functionalization, including reduced TNF-α expression and better prevention of mucosal damage. The nanoparticles were designed to target colonic epithelial cells and macrophages, showed appropriate size and charge properties, and appeared nontoxic to intestinal cells in vitro. The results suggest the delivery system enables KPV internalization into target cells and exerts combined effects on mucosal healing and inflammation reduction.
Summaries are our own; we link to originals (PubMed / DOI) and never rehost full text.
Regulatory status
- FDA approved
- No
- WADA prohibited
- No
- Notes
- Operator review required.
Legal/regulatory status varies by jurisdiction and changes over time — accurate as of last review (2026-06-04).
Data sources: Curated IDs (PubChem/UniProt/ChEMBL) + Europe PMC + ClinicalTrials.gov (2026-06-04).
Last reviewed 2026-06-04